Janssen Pharmaceuticals, Inc. Becomes Official Cardiovascular Partner of NASCAR

NASCAR announced today that it is teaming up with Janssen Pharmaceuticals, Inc., to help make a difference for racing fans who are at risk for or are living with blood clots. Janssen, the maker of XARELTO® (rivaroxaban), an important medicine used to treat and help prevent blood clots, is now the Official Cardiovascular Partner of NASCAR.
“We are encouraged to see Janssen Pharmaceuticals’ level of dedication to helping fans affected by blood clots,” said Jim O’Connell, NASCAR chief sales officer. “We welcome them to the NASCAR family, not only as an Official Partner but also as a race entitlement and team sponsor.”
Blood clots have hit close to home for the NASCAR community. Brian Vickers, full-time driver of the No. 55 Aaron’s Dream Machine Toyota for Michael Waltrip Racing in the NASCAR Sprint Cup Series, recently overcame his second episode with the condition. Having completed his treatment with XARELTO® and being cleared by his physician, Brian is now competing again in the NASCAR Sprint Cup Series and is currently 18th in points, with a top-10 finish at the Food City 500 at Bristol Motor Speedway on Sunday, March 16.
“I’m so grateful for all of the fans who have reached out to me to show their support,” said Vickers. “When I had my first deep vein thrombosis in 2010, I did everything I could to treat it and get back to racing. It worked, but the drug I was prescribed required me to have my blood drawn a lot and avoid certain foods. The second blow came when I developed another clot last year. While it was hard to be away from the track until I completed my treatment, I was relieved that this time around my doctor prescribed me XARELTO®,which didn’t require me to have my blood checked regularly or change my diet.”
Brian Vickers will be competing at the Auto Club Speedway in a custom TREATMYCLOT.COM Aaron’s Dream Machine Toyota Camry co-sponsored by Janssen on March 23, 2014. Additionally, TREATMYCLOT.COM will serve as title sponsor of the NASCAR Nationwide Series race at Auto Club Speedway. The TREATMYCLOT.COM 300 is scheduled to air on ESPN on Saturday, March 22 at 5 p.m. ET.
900,000 Americans experience blood clots every year2 that result in nearly 300,000 deaths.  According to The National Blood Clot Alliance, many factors can increase a person’s risk for developing blood clots, including age; being overweight; having other chronic diseases; immobility; hormones and pregnancy; long air travel; surgery; trauma or injury.1
The National Association for Stock Car Auto Racing, Inc. (NASCAR) is the sanctioning body for the No. 1 form of motorsports in the United States. NASCAR consists of three national series (the NASCAR Sprint Cup Series, NASCAR Nationwide Series, and NASCAR Camping World Truck Series), four regional series, one local grassroots series and three international series. The International Motor Sports Association (IMSA) governs the TUDOR United SportsCar Championship, the premier U.S. sports car series. Based in Daytona Beach, Fla., with offices in eight cities across North America, NASCAR sanctions more than 1,200 races in more than 30 U.S. states, Canada, Mexico and Europe. For more information visit and follow NASCAR at and Twitter: @NASCAR.
About Janssen Pharmaceuticals, Inc.
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Please visit for more information.
About XARELTO® (rivaroxaban)
XARELTO® works by blocking the blood clotting Factor Xa and does not require routine blood monitoring. XARELTO®has the broadest indication profile of any novel oral anticoagulant and is approved for six indications that include:
1.             To reduce the risk of strokes and blood clots in patients with atrial fibrillation not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO®and warfarin compare in reducing the risk of stroke.
2.             To treat patients with deep vein thrombosis (DVT).
3.             To treat patients with pulmonary embolism (PE).
4.             To reduce the risk of recurrence of DVT or PE following an initial six-month treatment for acute venous thromboembolism.
5.             To reduce the risk of blood clots in the legs and lungs of patients who have just had knee replacement surgery.
6.             To reduce the risk of blood clots in the legs and lungs of patients who have just had hip replacement surgery.
Eight million patients have received XARELTO® worldwide, and more than five million prescriptions have been written for XARELTO® in the U.S. XARELTO® has earned a strong reimbursement profile among oral anticoagulants, with 90 percent of patients on Medicare Part D and 90 percent of commercial patients covered at the lowest branded co-pay.
Janssen Research & Development, LLC and Bayer HealthCare together are developing rivaroxaban.
For more information about XARELTO®,visit TREATMYCLOT.COM. The XARELTO® CarePath™ Support Program is a resource designed for healthcare providers, patients and caregivers. Visit or call 1-888-XARELTO to learn more about the XARELTO® CarePath™ resources focused on access, education and adherence.

About Evan Schumacher

Thank you for taking the time and checking out my site. Please poke around and feel free to leave a comment.

No comments yet... Be the first to leave a reply!

What is your opinion?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: